Lv5
880 积分 2025-11-07 加入
Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors
2个月前
已完结
The impact of axillary lymph-node dissection omission on adjuvant abemaciclib eligibility in HR-positive, HER2-negative breast cancer with positive sentinel lymph nodes
2个月前
已完结
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?
2个月前
已完结
Risk of pN2/3 Understaging in Sentinel Node-Positive ER+/HER2− Breast Cancer: A Composite Clinicopathologic Score for Safe RxPONDER and MonarchE Application
2个月前
已完结
Real-World Outcomes of Abemaciclib Dose-Escalation Strategy in High-Risk Early Breast Cancer
2个月前
已关闭
Overall survival with abemaciclib in early breast cancer
2个月前
已完结
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancer
2个月前
已关闭
Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer
2个月前
已完结
Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence
2个月前
已完结
Nomogram Utilizing ABVS Radiomics and Clinical Factors for Predicting ≤ 3 Positive Axillary Lymph Nodes in HR+ /HER2- Breast Cancer with 1–2 Positive Sentinel Nodes
2个月前
已完结
皖公网安备34019202002308
